Journal of Applied Physiology Watch the video to see how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

J Appl Physiol (June 26, 2008). doi:10.1152/japplphysiol.90529.2008 Free Article
This Article
Free upon publication Free Article
Right arrow Full Text (PDF) Free
Right arrow All Versions of this Article:
105/2/417    most recent
90529.2008v1
Right arrow Submit a response
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lundby, C.
Right arrow Articles by Robach, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lundby, C.
Right arrow Articles by Robach, P.
Submitted on April 16, 2008
Revised on June 4, 2008
Accepted on June 10, 2008

Testing for recombinant human erythropoietin in urine: problems associated with current anti doping testing

Carsten Lundby1*, Niels Jacob Achman-Andersen, Jonas Juhl Thomsen, Anne M Norgaard, and Paul Robach

1 Copenhagen Muscle Research Centre

* To whom correspondence should be addressed. E-mail: lundby{at}idraet.au.dk.

Background: The main action of recombinant human erythropoietin (rHuEpo) is to increase the oxygen carrying capacity of the blood. To prevent a possible misuse of rHuEpo, this is tested in urine samples collected from athletes by World Anti Doping Agency (WADA) accredited laboratories. Recently the test has met serious critiques, and the aims of the present study were to investigate the detection power of the test as well as the variability in the test power comparing the results of two WADA accredited laboratories. Methods: Eight human subjects were studied for seven weeks and treated with rHuEpo for four weeks with two weeks of "boosting" followed by two weeks of "maintenance" and a post period of three weeks. Urine samples were obtained during all periods. Results: Laboratory A determined rHuEpo misuse in all subjects during the "boosting" period, whereas Laboratory B found no misuse, with one sample to be negative, and the remaining seven to be suspicious. The detection rates decreased throughout the maintenance and post period when total hemoglobin mass and exercise performance were elevated. During this period, laboratory A found only two out of 24 samples to be positive, and three to be suspicious, and laboratory B found no positive or suspicious samples. Conclusion: This study demonstrates a poor agreement in test results comparing two WADA accredited laboratories. Moreover, after the initial rHuEpo "boosting" period the power to detect rHuEpo misuse during the maintenance and post periods appears minimal.




This article has been cited by other articles:


Home page
 BloodHome page
P. Robach, S. Recalcati, D. Girelli, C. Gelfi, N. J. Aachmann-Andersen, J. J. Thomsen, A. M. Norgaard, A. Alberghini, N. Campostrini, A. Castagna, et al.
Alterations of systemic and muscle iron metabolism in human subjects treated with low-dose recombinant erythropoietin
Blood, June 25, 2009; 113(26): 6707 - 6715.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
G. Lippi, G. Banfi, J. Morkeberg, B. Belhage, R. Damsgaard, and V. Skibeli
Comments on Delanghe and Joyner's editorial "testing for recombinant human erythropoietin".
J Appl Physiol, December 1, 2008; 105(6): 1990 - 1991.
[Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
G. Lippi, W. E. Jelkmann, G. L. Salvagno, G. C. Guidi, C. R. Valeri, G. Ragno, B. Kayser, F. Lasne, Y. O. Schumacher, T. Pottgiesser, et al.
Comments on Lundby et al.'s "testing for recombinant human erythropoietin in urine: problems associated with current anti-doping testing". Problems associated with current anti-doping testing: is quality assessment a reliable solution?
J Appl Physiol, December 1, 2008; 105(6): 1992 - 1993.
[Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
C. Lundby
Reply to Lippi et al.'s "Comments on 'Testing for recombinant human erythropoietin in urine: problems associated with current anti-doping testing' "
J Appl Physiol, December 1, 2008; 105(6): 1997 - 1998.
[Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
J. R. Delanghe and M. J. Joyner
Testing for recombinant human erythropoietin
J Appl Physiol, August 1, 2008; 105(2): 395 - 396.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 1948 by the American Physiological Society.